Elanco Animal Health Incorporated (NYSE:ELAN) reported fourth-quarter revenue of $1.02 billion, a decrease of 1% on a ...
Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $13 from $14 and keeps an Equal Weight rating on the shares. Q4 EPS of 14c ...
Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.
Elanco Animal Health inks agreement with Medgene to commercialize highly pathogenic avian influenza vaccine in dairy cattle: Greenfield, Indiana Wednesday, February 26, 2025, 15:0 ...
Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...
Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.
Elanco Animal Health (NYSE:ELAN) traded lower in the premarket on Tuesday after the veterinary product maker, with its Q4 2024 results, set its full-year outlook below consensus, citing an unfavorable ...
B, consensus $4.53B. “We are focused on accelerating organic constant currency revenue growth for 2025, with continued efforts to improve our earnings potential and leverage profile,” said Todd Young, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results